MedTrace Logo

Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants

NCT05260437 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 99

Last updated 2024-08-12

Study results available
· View outcomes & findings →

Summary

Prevention of COVID-19 caused by SARS-CoV-2.

Conditions

Interventions

BIOLOGICAL

CV2CoV (2 µg)

Study vaccine was administered as a single intramuscular injection.

BIOLOGICAL

CV2CoV (4 µg)

Study vaccine was administered as a single intramuscular injection.

BIOLOGICAL

CV2CoV (8 µg)

Study vaccine was administered as a single intramuscular injection.

BIOLOGICAL

CV2CoV (12 µg)

Study vaccine was administered as a single intramuscular injection.

BIOLOGICAL

CV2CoV (16 µg)

Study vaccine was administered as a single intramuscular injection.

BIOLOGICAL

CV2CoV (20 µg)

Study vaccine was planned to be administered intramuscularly. No vaccine was administered in the CV2CoV (20 µg) Group, since there were no participants enrolled in it.

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-24
Primary Completion
2023-03-07
Completion
2023-03-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05260437 on ClinicalTrials.gov